INCY
Price
$67.86
Change
-$1.08 (-1.57%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
13.34B
11 days until earnings call
TECH
Price
$52.03
Change
-$1.26 (-2.36%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
8.16B
25 days until earnings call
Interact to see
Advertisement

INCY vs TECH

Header iconINCY vs TECH Comparison
Open Charts INCY vs TECHBanner chart's image
Incyte
Price$67.86
Change-$1.08 (-1.57%)
Volume$39.51K
Capitalization13.34B
Bio-Techne
Price$52.03
Change-$1.26 (-2.36%)
Volume$51.99K
Capitalization8.16B
INCY vs TECH Comparison Chart in %
Loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCY vs. TECH commentary
Jul 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and TECH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 19, 2025
Stock price -- (INCY: $68.94 vs. TECH: $53.29)
Brand notoriety: INCY: Notable vs. TECH: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 42% vs. TECH: 58%
Market capitalization -- INCY: $13.34B vs. TECH: $8.16B
INCY [@Biotechnology] is valued at $13.34B. TECH’s [@Biotechnology] market capitalization is $8.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 1 FA rating(s) are green whileTECH’s FA Score has 1 green FA rating(s).

  • INCY’s FA Score: 1 green, 4 red.
  • TECH’s FA Score: 1 green, 4 red.
According to our system of comparison, TECH is a better buy in the long-term than INCY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 4 TA indicator(s) are bullish while TECH’s TA Score has 4 bullish TA indicator(s).

  • INCY’s TA Score: 4 bullish, 2 bearish.
  • TECH’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, INCY is a better buy in the short-term than TECH.

Price Growth

INCY (@Biotechnology) experienced а -1.99% price change this week, while TECH (@Biotechnology) price change was -2.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.49%. For the same industry, the average monthly price growth was +13.01%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

INCY is expected to report earnings on Nov 04, 2025.

TECH is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+2.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($13.3B) has a higher market cap than TECH($8.16B). INCY has higher P/E ratio than TECH: INCY (344.70) vs TECH (62.67). INCY YTD gains are higher at: -0.188 vs. TECH (-25.807). INCY has higher annual earnings (EBITDA): 407M vs. TECH (283M). INCY has more cash in the bank: 2.41B vs. TECH (141M). INCY has less debt than TECH: INCY (43.1M) vs TECH (423M). INCY has higher revenues than TECH: INCY (4.41B) vs TECH (1.21B).
INCYTECHINCY / TECH
Capitalization13.3B8.16B163%
EBITDA407M283M144%
Gain YTD-0.188-25.8071%
P/E Ratio344.7062.67550%
Revenue4.41B1.21B365%
Total Cash2.41B141M1,709%
Total Debt43.1M423M10%
FUNDAMENTALS RATINGS
INCY vs TECH: Fundamental Ratings
INCY
TECH
OUTLOOK RATING
1..100
1165
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8980
PRICE GROWTH RATING
1..100
5363
P/E GROWTH RATING
1..100
146
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (4) in the Biotechnology industry is significantly better than the same rating for INCY (92). This means that TECH’s stock grew significantly faster than INCY’s over the last 12 months.

TECH's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as INCY (100). This means that TECH’s stock grew similarly to INCY’s over the last 12 months.

TECH's SMR Rating (80) in the Biotechnology industry is in the same range as INCY (89). This means that TECH’s stock grew similarly to INCY’s over the last 12 months.

INCY's Price Growth Rating (53) in the Biotechnology industry is in the same range as TECH (63). This means that INCY’s stock grew similarly to TECH’s over the last 12 months.

INCY's P/E Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for TECH (46). This means that INCY’s stock grew somewhat faster than TECH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYTECH
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
59%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 9 days ago
61%
Bullish Trend 2 days ago
71%
Declines
ODDS (%)
Bearish Trend 19 days ago
62%
Bearish Trend 4 days ago
72%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFNCX89.330.31
+0.35%
American Funds Fundamental Invs 529C
THVRX29.89N/A
N/A
Thornburg International Equity R4
HMVSX17.54N/A
N/A
Hartford MidCap Value R4
CEFAX13.86N/A
N/A
Calvert Emerging Markets Advancement A
SBRVX14.90N/A
N/A
Segall Bryant & Hamill Sm Cp Val Ret